Tarloxotinib is the company’s hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand. The company noted that elevated expression
Earlier, the FDA has approved Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin), while Synjardy is the third product containing empagliflozin that received approval from the agency. Both empagliflozin and metformin
The company paid $232 per share in cash for Receptos, which is focused on developing therapeutic candidates to treat immune and metabolic diseases. The acquisition of Receptos builds
Under the deal, Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply. RHB-105 is a new fixed-dose oral combination
Corium, a US-based biopharmaceutical firm, is focused on the development, manufacture and commercialization of specialty transdermal products. The MicroCor system is a clinical-stage platform technology using dissolving microstructures
Nanotherapeutics acquired Vero cell technology from Baxalta, formerly Baxter International’s BioScience division. Earlier in 2010, Takeda licensed from Baxter certain exclusive rights to the technology to develop pandemic
In the US market, Alvogen has a pipeline of more than 60 ANDA’s, of which 28 have first-to-file or first-to-market potential. The deal will further diversify and strengthen
AT001 is developed based on adeno-associated virus (AAV) gene therapy technology that is designed to restore the ability of skeletal muscle to produce myotubularin. XLMTM affects skeletal muscles
The investment made into these facilities will see creation of about 700 new production and engineering jobs in Clayton, North Carolina where it now employs more than 700
Entinostat is an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)) and atezolizumab is a fully humanized monoclonal antibody
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.